Assembly Biosciences (NASDAQ:ASMB) & CytoDyn (OTCMKTS:CYDY) Head-To-Head Survey

Assembly Biosciences (NASDAQ:ASMB) and CytoDyn (OTCMKTS:CYDY) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.

Institutional & Insider Ownership

19.9% of Assembly Biosciences shares are owned by institutional investors. Comparatively, 5.1% of CytoDyn shares are owned by institutional investors. 5.1% of Assembly Biosciences shares are owned by company insiders. Comparatively, 0.5% of CytoDyn shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Risk and Volatility

Assembly Biosciences has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500. Comparatively, CytoDyn has a beta of 0.01, meaning that its stock price is 99% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Assembly Biosciences and CytoDyn, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Assembly Biosciences	0	1	1	0	2.50
CytoDyn	0	0	0	0	0.00

Assembly Biosciences presently has a consensus price target of $35.00, suggesting a potential upside of 156.22%. Given Assembly Biosciences’ stronger consensus rating and higher possible upside, analysts clearly believe Assembly Biosciences is more favorable than CytoDyn.

Profitability

This table compares Assembly Biosciences and CytoDyn’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Assembly Biosciences	-144.05%	-121.46%	-34.56%
CytoDyn	N/A	N/A	-76.70%

Earnings & Valuation

This table compares Assembly Biosciences and CytoDyn”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Assembly Biosciences	$7.16 million	12.13	-$61.23 million	N/A	N/A
CytoDyn	$270,000.00	975.19	-$49.84 million	($0.01)	-21.40

CytoDyn has lower revenue, but higher earnings than Assembly Biosciences.

Summary

Assembly Biosciences beats CytoDyn on 8 of the 12 factors compared between the two stocks.

About Assembly Biosciences

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

About CytoDyn

CytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.